---
schema_version: "secwatch.filing_event.v1"
accession: "0001087294-25-000017"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:32:15.947634+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma reports Q3 net loss of $1.9M; YTD revenue up 12% to $30.8M

## Summary
- Net revenue for Q3 2025 was $8.3M; YTD $30.8M (+12% vs. 2024).
- Net loss Q3 $1.9M; YTD net loss $1.4M. Adjusted loss Q3 $0.8M ($0.06/sh); adjusted earnings YTD $1.9M ($0.13/sh).
- Added Talicia via joint venture with RedHill: Cumberland invests $4M for 30% ownership; net revenue split equally.
- Vibativ launched in Saudi Arabia; ibuprofen injection approved in Mexico; Vibativ available through Vizient.
- Ifetroban Phase II DMD showed 5.4% cardiac improvement; Phase II SSc enrollment complete; IPF trial enrolling.

## SEC filing metadata
- accession: 0001087294-25-000017
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000108729425000017/0001087294-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000108729425000017/cpix-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001087294-25-000017
- JSON: https://secwatch.observer/filing/0001087294-25-000017.json
- Plain text: https://secwatch.observer/filing/0001087294-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.